Network meta-analyses (NMAs) are a methods, which allows indirect comparisons of several medications. Indirect comparisons play an important role in the assessment of the cost-benefit ratio of drugs.
(more…)
Biomarker play an important role in modern pharmaceutical development because they allow a treatment adjusted for the patient’s individual circumstances. Recommendation for specific therapies for example based on the patient’s very own gene mutation profile (keyword “Precision Medicine”) take the place of the predominant “one-size-fits-all” approach.
In clinical trials, a treatment’s efficiency and safety is measured and evaluated. In oncology, standards have been developed to enable the harmonization of study results. These criteria are used for efficiency (response of treatment) as well as for safety (e.g. to detect a progression in time) evaluation.
Recent Comments